203 related articles for article (PubMed ID: 17040473)
21. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity.
Hampson RE; Miller F; Palchik G; Deadwyler SA
Neuropharmacology; 2011 May; 60(6):944-52. PubMed ID: 21288475
[TBL] [Abstract][Full Text] [Related]
22. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
[TBL] [Abstract][Full Text] [Related]
23. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat.
Antonelli T; Tanganelli S; Tomasini MC; Finetti S; Trabace L; Steardo L; Sabino V; Carratu MR; Cuomo V; Ferraro L
Neuroscience; 2004; 124(2):367-75. PubMed ID: 14980386
[TBL] [Abstract][Full Text] [Related]
25. Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo.
Pillolla G; Melis M; Perra S; Muntoni AL; Gessa GL; Pistis M
Psychopharmacology (Berl); 2007 Apr; 191(3):843-53. PubMed ID: 17334799
[TBL] [Abstract][Full Text] [Related]
26. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
Suplita RL; Eisenstein SA; Neely MH; Moise AM; Hohmann AG
Neuropharmacology; 2008 Jan; 54(1):161-71. PubMed ID: 17714742
[TBL] [Abstract][Full Text] [Related]
27. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain.
Cenni G; Blandina P; Mackie K; Nosi D; Formigli L; Giannoni P; Ballini C; Della Corte L; Mannaioni PF; Passani MB
Eur J Neurosci; 2006 Sep; 24(6):1633-44. PubMed ID: 17004927
[TBL] [Abstract][Full Text] [Related]
28. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation.
Rodella LF; Borsani E; Rezzani R; Ricci F; Buffoli B; Bianchi R
Eur J Pharmacol; 2005 Jan; 508(1-3):139-46. PubMed ID: 15680264
[TBL] [Abstract][Full Text] [Related]
29. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.
Béquet F; Uzabiaga F; Desbazeille M; Ludwiczak P; Maftouh M; Picard C; Scatton B; Le Fur G
Eur J Neurosci; 2007 Dec; 26(12):3458-64. PubMed ID: 18052990
[TBL] [Abstract][Full Text] [Related]
30. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats.
Petrosino S; Palazzo E; de Novellis V; Bisogno T; Rossi F; Maione S; Di Marzo V
Neuropharmacology; 2007 Feb; 52(2):415-22. PubMed ID: 17011598
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
32. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
33. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain.
Monhemius R; Azami J; Green DL; Roberts MH
Brain Res; 2001 Jul; 908(1):67-74. PubMed ID: 11457432
[TBL] [Abstract][Full Text] [Related]
34. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.
Ho WS; Gardiner SM
Br J Pharmacol; 2009 Jan; 156(1):94-104. PubMed ID: 19133994
[TBL] [Abstract][Full Text] [Related]
35. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain.
Herzberg U; Eliav E; Bennett GJ; Kopin IJ
Neurosci Lett; 1997 Jan; 221(2-3):157-60. PubMed ID: 9121688
[TBL] [Abstract][Full Text] [Related]
36. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
37. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.
Shivachar AC
Biochem Pharmacol; 2007 Jun; 73(12):2004-11. PubMed ID: 17445778
[TBL] [Abstract][Full Text] [Related]
39. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve.
Costa B; Trovato AE; Colleoni M; Giagnoni G; Zarini E; Croci T
Pain; 2005 Jul; 116(1-2):52-61. PubMed ID: 15936882
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.
Sagar DR; Kelly S; Millns PJ; O'Shaughnessey CT; Kendall DA; Chapman V
Eur J Neurosci; 2005 Jul; 22(2):371-9. PubMed ID: 16045490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
